EPIX Pharmaceuticals, Inc. Form 4 August 01, 2008									
				-	PROVAL				
UNITE	OMB Number:	3235-0287							
Check this box if no longer subject to Section 16. Form 4 or	MENT OF CHA	NGES IN BENEFICIAL O SECURITIES	WNERSHIP OF	burden hour	Estimated average burden hours per				
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations May continue. See Instruction 1(b). Continue (Continue)									
(Print or Type Responses)									
1. Name and Address of Reportin GAMZU ELKAN R	Symbo	uer Name and Ticker or Trading l Pharmaceuticals, Inc. [EPIX]	5. Relationship of Reporting Person(s) to Issuer						
(Last) (First)	(Check all applicable)								
C/O EPIX PHARMACEUT INC., 4 MAGUIRE ROAD	(Month	e of Earliest Transaction n/Day/Year) /2008	Director 10% Owner X Officer (give title Other (specify below) below) Chief Executive Officer						
(Street)	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
LEXINGTON, MA 02421			Person	fore than One Rej	porting				
(City) (State)	(Zip) Ta	able I - Non-Derivative Securities	Acquired, Disposed of	f, or Beneficiall	ly Owned				
1.Title of Security (Instr. 3)2. Transaction Dat (Month/Day/Year)	Execution Date, if any	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price	SecuritiesFBeneficially(2)Owned(2)Following(2)ReportedTransaction(s)(Instr. 3 and 4)	Form: Direct D) or Indirect I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
Reminder: Report on a separate lin	ne for each class of se	ecurities beneficially owned directly	or indirectly.						
		information con required to resp	spond to the collec itained in this form oond unless the forr ently valid OMB con	are not n	EC 1474 (9-02)				

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 2.1	07/31/2008		A		300,000		<u>(1)</u>	07/31/2018	Common Stock	300,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
F	Director	10% Owner	Officer	Other			
GAMZU ELKAN R C/O EPIX PHARMACEUTICALS, INC. 4 MAGUIRE ROAD LEXINGTON, MA 02421			Chief Executive Officer				
Signatures							
/s/ Kim Cobleigh Drapkin, Attorney-in-Fact	08	/01/2008					
**Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests in nine (9) tranches. The first tranche of 33,336 shares vests on July 31, 2008, and the remaining eight (8) tranches shall vest in consecutive equal monthly installments of 33,333 shares commencing on August 31, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.